Updating results

High-intensity focused ultrasound for symptomatic breast fibroadenoma (IPG592)

Evidence-based recommendations on high-intensity focused ultrasound for symptomatic breast fibroadenoma (benign/non-cancerous lumps in the breast)

Interventional procedures guidance Published September 2017

Ab externo canaloplasty for primary open-angle glaucoma (IPG591)

Evidence-based recommendations on ab externo canaloplasty (widening eye’s main draining canal) for primary open-angle glaucoma (damaged optic nerve)

Interventional procedures guidance Published September 2017

Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults

Technology appraisal guidance Published October 2015 Last updated September 2017

Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults not previously treated with ipilimumab

Technology appraisal guidance Published November 2015 Last updated September 2017

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

Evidence-based recommendations on pembrolizumab (Keytruda) for locally advanced or metastatic PD-L1-positive non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published January 2017 Last updated September 2017

Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) for untreated metastatic pancreatic cancer in adults

Technology appraisal guidance Published September 2017

Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published September 2017

Sorafenib for treating advanced hepatocellular carcinoma (TA474)

Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma (liver cancer) in adults

Technology appraisal guidance Published September 2017

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults

Technology appraisal guidance Published August 2017

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for adults with follicular lymphoma unresponsive to treatment with rituximab

Technology appraisal guidance Published August 2017

Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)

Evidence-based recommendations on eluxadoline (Truberzi) for treating irritable bowel syndrome (IBS) with diarrhoea in adults

Technology appraisal guidance Published August 2017

Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)

NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence

Technology appraisal guidance Published August 2017

Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) (TA468)

NICE was unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence was

Technology appraisal guidance Published August 2017

Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) (TA470)

This advice has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

Technology appraisal guidance Published August 2017

Radiofrequency treatment for haemorrhoids (IPG589)

Evidence-based recommendations on radiofrequency treatment for haemorrhoids in adults

Interventional procedures guidance Published August 2017

Liposuction for chronic lymphoedema (IPG588)

Evidence-based recommendations on liposuction for chronic lymphoedema in adults to remove build-up of fluid and excess fat tissue in limbs

Interventional procedures guidance Published August 2017

Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG590)

Evidence-based recommendations on biodegradable spacer insertion (gel or balloon) to reduce rectal toxicity during radiotherapy for prostate cancer in adults

Interventional procedures guidance Published August 2017

Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns

Technology appraisal guidance Published August 2017

Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2010 Last updated August 2017

Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma (kidney cancer) in adults

Technology appraisal guidance Published August 2017

Baricitinib for moderate to severe rheumatoid arthritis (TA466)

Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults

Technology appraisal guidance Published August 2017

Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children

Highly specialised technologies guidance Published August 2017

Transcatheter aortic valve implantation for aortic stenosis (IPG586)

Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for aortic stenosis

Interventional procedures guidance Published July 2017

Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (IPG585)

Evidence-based recommendations on laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (GORD) in adults

Interventional procedures guidance Published July 2017

Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (DG30)

Evidence-based recommendations on quantitative faecal immunochemical tests (OC Sensor, HM-JACKarc and FOB Gold) to guide GP referral for colorectal cancer

Diagnostics guidance Published July 2017

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults

Technology appraisal guidance Published July 2017

Roflumilast for treating chronic obstructive pulmonary disease (TA461)

Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease (COPD) in adults with chronic bronchitis

Technology appraisal guidance Published July 2017

Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

Evidence-based recommendations on collagenase clostridium histolyticum (Xiapex) for treating Dupuytren’s contracture in adults

Technology appraisal guidance Published July 2017

Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults

Technology appraisal guidance Published July 2017

Carfilzomib for previously treated multiple myeloma (TA457)

Evidence-based recommendations on carfilzomib (Kyprolis) for treating multiple myeloma in adults

Technology appraisal guidance Published July 2017

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults

Technology appraisal guidance Published July 2017

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for treating plaque psoriasis in children and young people

Technology appraisal guidance Published July 2017

New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners (DG3)

Evidence-based recommendations on new generation computed tomography (CT) scanners for cardiac imaging for suspected or known coronary artery disease

Diagnostics guidance Published January 2012 Last updated July 2017

Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA454)

NICE was unable to make a recommendation about the use in the NHS of daratumumab with lenalidomide and dexamethasone for multiple myeloma because no evidence

Technology appraisal guidance Published July 2017

Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) (TA452)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53

Technology appraisal guidance Published July 2017

Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) (TA453)

NICE is unable to make a recommendation about the use in the NHS of bortezomib for treating multiple myeloma after second or subsequent relapse because no

Technology appraisal guidance Published July 2017

Infracoccygeal sacropexy using mesh to repair uterine prolapse (IPG582)

Evidence-based recommendations on infracoccygeal sacropexy using mesh to repair uterine (womb) prolapse in women

Interventional procedures guidance Published June 2017

Infracoccygeal sacropexy using mesh to repair vaginal vault prolapse (IPG581)

Evidence-based recommendations on infracoccygeal sacropexy using mesh to repair vaginal vault prolapse in women

Interventional procedures guidance Published June 2017

Sacrocolpopexy using mesh to repair vaginal vault prolapse (IPG583)

Evidence-based recommendations on sacropolpopexy using mesh to repair vaginal vault prolapse in women

Interventional procedures guidance Published June 2017

Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse (IPG584)

Evidence-based recommendations on uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse in women

Interventional procedures guidance Published June 2017

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults

Technology appraisal guidance Published June 2017

Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults

Technology appraisal guidance Published June 2017

Etelcalcetide for treating secondary hyperparathyroidism (TA448)

Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis

Technology appraisal guidance Published June 2017

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)

This guidance has been updated and replaced by NICE technology appraisal guidance 531.

Technology appraisal guidance Published June 2017

Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)

Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults

Technology appraisal guidance Published June 2017

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

This guidance has been updated and replaced by NICE technology appraisal guidance 524.

Technology appraisal guidance Published June 2017

Eliglustat for treating type 1 Gaucher disease (HST5)

Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults

Highly specialised technologies guidance Published June 2017

Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29)

Evidence-based recommendations on multi frequency bioimpedance devices to guide fluid management for people with chronic kidney disease having dialysis

Diagnostics guidance Published June 2017

Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA444)

NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy

Technology appraisal guidance Published May 2017